LakeShore Biopharma (LSB) has released an update.
LakeShore Biopharma has announced significant leadership changes, appointing Xu Wang as the new CEO and Dr. Hui Shao as both the Chief Business Officer and Vice Chairman of the Board. Further consolidating its management team, Rachel Yu has been named the permanent Chief Financial Officer. These strategic appointments, effective from September 1, 2024, are aimed to reinforce the company’s commitment to advancing biopharmaceuticals for infectious diseases and cancer.
For further insights into LSB stock, check out TipRanks’ Stock Analysis page.
